🇺🇸 FDA
Patent

US 9642898

Use of serine protease inhibitors in the treatment of neutropenia

granted A61KA61K35/15A61K35/28

Quick answer

US patent 9642898 (Use of serine protease inhibitors in the treatment of neutropenia) held by MED DISCOVERY S.A. expires Mon May 04 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
MED DISCOVERY S.A.
Grant date
Tue May 09 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 04 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61K, A61K35/15, A61K35/28, A61K38/1709, A61K38/57